AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Novo Nordisk Downgraded to Hold by HSBC Amid Concerns Over Growth Trajectory
ByAinvest
Saturday, Aug 2, 2025 5:10 am ET1min read
Novo Nordisk was downgraded to Hold from Buy at HSBC due to the company's warning that its 2025 exit growth rate will likely settle into mid-single digits. The adjustment reflects concerns over Novo Nordisk's growth trajectory and structural challenges.
Novo Nordisk, a leading global healthcare company, has been downgraded to Hold from Buy by HSBC, reflecting mounting concerns over the company's growth trajectory and structural challenges. The downgrade comes following Novo Nordisk's recent warning that its 2025 exit growth rate is expected to settle into mid-single digits [1].The downgrade is attributed to several factors, including the continued illegal selling of weight loss drugs by U.S. compounders despite FDA bans, which has prevented Novo Nordisk from regaining expected market share in the GLP-1 drug market [2]. Additionally, HSBC raised concerns about the overestimation of the GLP-1 market size and questioned the safety of medium-term pricing assumptions given capacity investments in the space [2].
HSBC acknowledged that their previous Buy rating was incorrect, noting that their assumption about the FDA ban on compounding allowing Novo Nordisk to regain market share has not materialized [2]. The research firm also highlighted internal management changes and execution delays as factors contributing to the reduced confidence in Novo Nordisk's short-term earnings outlook [2].
The downgrade reflects a broader trend of concern over Novo Nordisk's growth trajectory and structural weaknesses in the GLP-1 market, which underpins much of the company's sales momentum [2]. Earnings for 2025 and 2026 have been revised downward by 5% and 16%, respectively, with HSBC lowering its target price from DKK680 to DKK360 [2].
References:
[1] https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=916407
[2] https://seekingalpha.com/news/4475685-novo-nordisk-downgraded-to-hold-at-hsbc-on-guidance-cut
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet